BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics
This article was originally published in The Pink Sheet Daily
The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.
You may also be interested in...
"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.
The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.